Economic analysis of Noqturina® (oral lyophilisate) use in the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2018, Vol 2, Issue 2
Abstract
Introduction: Nocturia relates to the need to urinate at night when micturition was preceded by sleep and immediately followed by a period of sleep. The aim of this analysis is to examine the cost-effectiveness of desmopressin at a dose of 25 μg oral lyophilisate for women and 50 μg oral lyophilisate for men (DDAVP) in comparison to the best supportive care (BSC) used in Polish clinical practice in the treatment of nocturia (≥2 nocturnal micturition) caused by idiopathic nocturnal polyuria. Methods: The economic analysis uses a model combining the aspects of the partitioned-survival model and state-transition model (STM). The projection was carried out over a 30-year time horizon, which corresponds to 120 quarterly modelling cycles. The costs were calculated from a common perspective, including expenses incurred by the public payer (Narodowy Fundusz Zdrowia, National Health Found) and expenses incurred by the patient. Health effects of medical technologies have been estimated on the basis of unit data from CS40 and CS41 studies. The literature, statistical databases and information provided by clinical experts were used to develop the remaining input data, including utility. Results: The ICER for DDAVP + BSC compared to BSC was 56.1 kPLN (13.0 kEUR) and is below the cost-effectiveness threshold in force in Poland (135.5 kPLN; 31.2 kEUR). The multi-directional sensitivity analysis shows a profitability rate of 98.6%. Conclusions: The economic model shows that the addition of orodispersible DDAVP to standard treatment allows reducing the expected number of nocturnal micturition, improving the quality of life and reducing the number of injuries and fractures in the group of patients with nocturia caused by idiopathic nocturnal polyuria. Considering the total direct medical costs of treatment, desmopressin administered at a dose of 25 μg for women and 50 μg for men is a cost-effective therapy when added to the BSC.
Authors and Affiliations
Maciej Dzik, Grzegorz Binowski, Piotr Chłosta, Jakub Dobruch, Paweł Miotła, Tomasz Rechberger, Adam Bierut
Keywords
Related Articles
- EP ID EP532128
- DOI 10.7365/JHPOR.2018.2.1
- Views 58
- Downloads 0
Idiopathic Pulmonary Fibrosis as a Challenge for the Polish Healthcare System
Idiopathic pulmonary fibrosis (IPF) is a rare disease characterised by age-dependent incidence, unclear aetiology and progressive course. Given the complexity of the diagnostic pathway and limited therapeutic options, an...
The disposal of unused and/or out of date medications in the community pharmacy setting in Poland – a challenge for pharmaceutical public health and pharmaceutical care
It has been proven that even small concentrations of certain drugs in the environment can be toxic to plants, but also fatal for animals and humans. The only proper way to prevent this phenomenon is to minimize the adver...
Visualisation of the results of sequence analysis with the use of Sankey diagrams, based on prevalence analysis of selected medical problems in the years 2013-2015 in Poland
Introduction. The goal of the study is to assess the usefulness of Sankey model in the analysis of healthcare phenomena. Material and methods. Sequence analysis and Sankey model generation was based on the data provided...
The study of the need for interprofessional collaboration in the health care system in Poland - experience of Lesław A. Paga Foundation.
Background: Interprofessional collaboration (IC) in healthcare is a process by which professionals from different disciplines collaborate to provide an integrated and cohesive approach to patient care. The Lesław A. Paga...
Comparator outcomes profile: need for an informed assessment of secondary outcomes for conducting post-launch observational studies in the HE&OR setting
Secondary clinical and health outcomes provide additional value and help drug molecule distinguish itself from competitor molecules. Comparator outcomes profile (COP) document in health economics and outcomes research (H...